News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,211 Results
Type
Article (40646)
Company Profile (297)
Press Release (667268)
Multimedia
Podcasts (75)
Webinars (12)
Section
Business (207081)
Career Advice (2072)
Deals (35874)
Drug Delivery (100)
Drug Development (82388)
Employer Resources (176)
FDA (16257)
Job Trends (15171)
News (350104)
Policy (32868)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (6)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (7)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2574)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (50229)
ALS (90)
Alzheimer's disease (1401)
Antibody-drug conjugate (ADC) (131)
Approvals (16258)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (363)
Best Places to Work (11757)
BIOSECURE Act (21)
Biosimilars (108)
Biotechnology (212)
Bladder cancer (78)
Brain cancer (28)
Breast cancer (281)
Cancer (2265)
Cardiovascular disease (178)
Career advice (1728)
Career pathing (33)
CAR-T (151)
Cell therapy (426)
Cervical cancer (19)
Clinical research (67023)
Collaboration (846)
Compensation (531)
Complete response letters (21)
COVID-19 (2613)
CRISPR (39)
C-suite (246)
Cystic fibrosis (101)
Data (2213)
Decentralized trials (2)
Denatured (26)
Depression (46)
Diabetes (270)
Diagnostics (6387)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (95)
Earnings (87607)
Editorial (42)
Employer branding (23)
Employer resources (150)
Events (114778)
Executive appointments (732)
FDA (17508)
Featured Employer (52)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (749)
Gene editing (105)
Generative AI (20)
Gene therapy (305)
GLP-1 (736)
Government (4462)
Grass and pollen (5)
Guidances (59)
Healthcare (18899)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (30)
Infectious disease (2755)
Inflammatory bowel disease (138)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (97)
Interviews (328)
IPO (16744)
IRA (41)
Job creations (3837)
Job search strategy (1469)
Kidney cancer (10)
Labor market (38)
Layoffs (482)
Leadership (21)
Legal (7959)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (307)
MASH (70)
Medical device (13390)
Medtech (13395)
Mergers & acquisitions (19678)
Metabolic disorders (696)
Multiple sclerosis (81)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (29)
Neuroscience (1945)
NextGen: Class of 2025 (6571)
Non-profit (4499)
Northern California (2676)
Now hiring (40)
Obesity (370)
Opinion (222)
Ovarian cancer (76)
Pain (86)
Pancreatic cancer (83)
Parkinson's disease (150)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (58151)
Pharmaceutical (76)
Pharmacy benefit managers (19)
Phase I (20915)
Phase II (29574)
Phase III (21917)
Pipeline (1192)
Policy (149)
Postmarket research (2573)
Preclinical (8886)
Press Release (64)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (256)
Rare diseases (380)
Real estate (6031)
Recruiting (67)
Regulatory (22531)
Reports (46)
Research institute (2343)
Resumes & cover letters (354)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2301)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (31)
Startups (3657)
State (2)
Stomach cancer (13)
Supply chain (70)
Tariffs (40)
The Weekly (47)
United States (23209)
Vaccines (701)
Venture capitalists (42)
Weight loss (242)
Women's health (38)
Worklife (19)
Date
Today (123)
Last 7 days (853)
Last 30 days (2619)
Last 365 days (33237)
2025 (10646)
2024 (35730)
2023 (40661)
2022 (51785)
2021 (56339)
2020 (54535)
2019 (46980)
2018 (35385)
2017 (32635)
2016 (32060)
2015 (38110)
2014 (32005)
2013 (26893)
2012 (29013)
2011 (29668)
2010 (27706)
Location
Africa (741)
Alabama (58)
Alaska (7)
Arizona (233)
Arkansas (14)
Asia (39136)
Australia (6324)
California (6120)
Canada (2012)
China (539)
Colorado (269)
Connecticut (275)
Delaware (148)
Europe (84492)
Florida (916)
Georgia (204)
Idaho (57)
Illinois (532)
India (25)
Indiana (309)
Iowa (11)
Japan (160)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (901)
Massachusetts (4599)
Michigan (217)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1734)
New Mexico (29)
New York (1740)
North Carolina (1017)
North Dakota (8)
Northern California (2676)
Ohio (203)
Oklahoma (14)
Oregon (35)
Pennsylvania (1375)
Puerto Rico (13)
Rhode Island (33)
South America (1121)
South Carolina (22)
South Dakota (1)
Southern California (2301)
Tennessee (101)
Texas (908)
Utah (181)
Virginia (146)
Washington D.C. (62)
Washington State (560)
West Virginia (3)
Wisconsin (53)
708,211 Results for "immix biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
April 24, 2025
·
5 min read
Biotech Beach
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma, Inc. today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.
June 17, 2024
·
3 min read
Biotech Beach
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that Immix Biopharma is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
April 18, 2024
·
4 min read
Biotech Beach
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma.
April 29, 2024
·
4 min read
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
December 10, 2024
·
5 min read
Press Releases
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
January 8, 2025
·
7 min read
Press Releases
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
February 10, 2025
·
7 min read
Biotech Beach
Immix Biopharma 12 Month Review Progress Update
Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
February 21, 2024
·
11 min read
Biotech Beach
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of AL Amyloidosis.
February 7, 2024
·
6 min read
Biotech Beach
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
Immix Biopharma, Inc. announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock.
February 5, 2024
·
3 min read
1 of 70,822
Next
